Active immunization of hamsters against Clostridium difficile infection using surface-layer protein.

Clostridium difficile is the leading cause of infectious antibiotic-associated diarrhoea, particularly among the elderly. Its surface-layer protein (SLP) was tested as a vaccine component in a series of immunization and challenge experiments with Golden Syrian hamsters, combined with different systemic and mucosal adjuvants. Some regimens were also tested in a nonchallenge BALB/c mouse model, enabling closer monitoring of the immune response. None of the regimens conferred complete protection in the hamster model, and antibody stimulation was variable within regimens, and generally modest or poor. Mice displayed stronger antibody responses to SLP compared with hamsters. Two hamsters of five given SLP with Ribi (monophosphoryl lipid A and synthetic trehalose dicorynomycolate) survived the challenge, as did two of three given SLP with Ribi and cholera toxin. This modest trend to protection is interpreted with caution, because the survivors had low anti-SLP serum antibody titres. The hamsters were an outbred line, and subject to more genetic variability than inbred animals; however, BALB/c mice also showed strongly variable antibody responses. There is a clear need for better adjuvants for single-component vaccines, particularly for mucosal delivery. The hamster challenge model may need to be modified to be useful in active immunization experiments with SLP.

[1]  E. Fattal,et al.  Diminished intestinal colonization by Clostridium difficile and immune response in mice after mucosal immunization with surface proteins of Clostridium difficile. , 2007, Vaccine.

[2]  D. Kelleher,et al.  Passive immunisation of hamsters against Clostridium difficile infection using antibodies to surface layer proteins , 2005 .

[3]  J. Ballard,et al.  Clostridium difficile Toxins: Mechanism of Action and Role in Disease , 2005, Clinical Microbiology Reviews.

[4]  T. Monath,et al.  Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. , 2005, Gastroenterology.

[5]  S. Vitovski,et al.  Immunoglobulin A1 proteases: a structure-function update. , 2004, Biochemical Society transactions.

[6]  Louis Valiquette,et al.  Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity , 2004, Canadian Medical Association Journal.

[7]  S. Poutanen,et al.  Clostridium difficile-associated diarrhea in adults , 2004, Canadian Medical Association Journal.

[8]  U. Sleytr,et al.  A Novel Approach to Specific Allergy Treatment: The Recombinant Fusion Protein of a Bacterial Cell Surface (S-Layer) Protein and the Major Birch Pollen Allergen Bet v 1 (rSbsC-Bet v 1) Combines Reduced Allergenicity with Immunomodulating Capacity1 , 2004, The Journal of Immunology.

[9]  S. Ameer-Beg,et al.  Imaging protein-protein interactions in cell motility using fluorescence resonance energy transfer (FRET). , 2004, Biochemical Society transactions.

[10]  Y. Matsumoto,et al.  Clearance of Helicobacter pylori infection through immunization: the site of T cell activation contributes to vaccine efficacy. , 2004, Vaccine.

[11]  P. Giannasca,et al.  Active and passive immunization against Clostridium difficile diarrhea and colitis. , 2004, Vaccine.

[12]  V. Lund,et al.  The Aeromonas salmonicida A-layer protein is an important protective antigen in oil-adjuvanted vaccines. , 2003, Fish & shellfish immunology.

[13]  B. Lidbury,et al.  Antibody-dependent enhancement of infection: bacteria do it too. , 2003, Trends in immunology.

[14]  O. Leavy,et al.  Cholera Toxin Promotes the Induction of Regulatory T Cells Specific for Bystander Antigens by Modulating Dendritic Cell Activation 1 , 2003, The Journal of Immunology.

[15]  F. Audibert Adjuvants for vaccines, a quest. , 2003, International immunopharmacology.

[16]  M. Blaser,et al.  Role of S-Layer Protein Antigenic Diversity in the Immune Responses of Sheep Experimentally Challenged with Campylobacter fetus subsp. fetus , 2003, Infection and Immunity.

[17]  N. Fairweather,et al.  Binding of Clostridium difficile Surface Layer Proteins to Gastrointestinal Tissues , 2002, Infection and Immunity.

[18]  M. Murtaugh,et al.  Inflammatory cytokines and antigen presenting cell activation. , 2002, Veterinary immunology and immunopathology.

[19]  N. Fairweather,et al.  Patterns of Sequence Conservation in the S-Layer Proteins and Related Sequences in Clostridium difficile , 2002, Journal of bacteriology.

[20]  C. Kelly,et al.  Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  S. Davis,et al.  Chitosan as a novel nasal delivery system for vaccines. , 2001, Advanced drug delivery reviews.

[22]  N. Fairweather,et al.  Molecular characterization of the surface layer proteins from Clostridium difficile , 2001, Molecular microbiology.

[23]  D. Galloway,et al.  Protection against Pseudomonas aeruginosa Chronic Lung Infection in Mice by Genetic Immunization against Outer Membrane Protein F (OprF) of P. aeruginosa , 2001, Infection and Immunity.

[24]  M. Cerquetti,et al.  Molecular and Genomic Analysis of Genes Encoding Surface-Anchored Proteins from Clostridium difficile , 2001, Infection and Immunity.

[25]  T. Monath,et al.  Safety and Immunogenicity of Increasing Doses of aClostridium difficile Toxoid Vaccine Administered to Healthy Adults , 2001, Infection and Immunity.

[26]  J. Ward,et al.  Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration. , 2000, Vaccine.

[27]  Kearney,et al.  Clostridium difficile‐associated diarrhoea in hospitalised patients , 2000, Journal of clinical pharmacy and therapeutics.

[28]  R. Page Vaccination and periodontitis: myth or reality. , 2000, Journal of the International Academy of Periodontology.

[29]  D. Kelleher,et al.  The Thioredoxin System of Helicobacter pylori* , 2000, The Journal of Biological Chemistry.

[30]  S. Romero-Steiner,et al.  Correlation of opsonophagocytosis and passive protection assays using human anticapsular antibodies in an infant mouse model of bacteremia for Streptococcus pneumoniae. , 1999, The Journal of infectious diseases.

[31]  I. Poxton,et al.  Variation in the Cell Surface Proteins of Clostridium difficile , 1999 .

[32]  J. Brazier,et al.  PCR Targeted to the 16S-23S rRNA Gene Intergenic Spacer Region ofClostridium difficile and Construction of a Library Consisting of 116 Different PCR Ribotypes , 1999, Journal of Clinical Microbiology.

[33]  T. Monath,et al.  Serum Antitoxin Antibodies Mediate Systemic and Mucosal Protection from Clostridium difficileDisease in Hamsters , 1999, Infection and Immunity.

[34]  Gupta,et al.  Aluminum compounds as vaccine adjuvants. , 1998, Advanced drug delivery reviews.

[35]  J. Brazier The epidemiology and typing of Clostridium difficile. , 1998, The Journal of antimicrobial chemotherapy.

[36]  U. Sleytr,et al.  Toward selective elicitation of TH1-controlled vaccination responses: vaccine applications of bacterial surface layer proteins. , 1996, Journal of biotechnology.

[37]  T. Monath,et al.  Evaluation of formalin-inactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters , 1995, Infection and immunity.

[38]  A. Pantosti,et al.  Purification and characterization of an immunodominant 36 kDa antigen present on the cell surface of Clostridium difficile. , 1992, Microbial pathogenesis.

[39]  L. Trudel,et al.  Comparison of immune response potentiation and in vivo inflammatory effects of Freund's and RIBI adjuvants in mice. , 1992, Laboratory animal science.

[40]  M. Delmée,et al.  Characterization of flagella of Clostridium difficile and their role in serogrouping reactions , 1990, Journal of clinical microbiology.

[41]  G. Welling,et al.  The influence of different adjuvants on the immune response to a synthetic peptide comprising amino acid residues 9-21 of herpes simplex virus type 1 glycoprotein D. , 1989, Journal of immunological methods.

[42]  A. Pantosti,et al.  Immunoblot analysis of serum immunoglobulin G response to surface proteins of Clostridium difficile in patients with antibiotic-associated diarrhea , 1989, Journal of clinical microbiology.

[43]  J. Kenney,et al.  Influence of adjuvants on the quantity, affinity, isotype and epitope specificity of murine antibodies. , 1989, Journal of immunological methods.

[44]  W. Stamm,et al.  Nosocomial acquisition of Clostridium difficile infection. , 1989, The New England journal of medicine.

[45]  A. Price,et al.  Clostridium difficile--a spectrum of virulence and analysis of putative virulence determinants in the hamster model of antibiotic-associated colitis. , 1987, Journal of medical microbiology.

[46]  K. Saum,et al.  Effects of Clostridium difficile toxins given intragastrically to animals , 1985, Infection and immunity.

[47]  J. Bartlett,et al.  Clostridium difficile in gnotobiotic mice , 1980, Infection and immunity.

[48]  A. Ryan,et al.  Sequence and phylogenetic analysis of the gene for surface layer protein, slpA, from 14 PCR ribotypes of Clostridium difficile. , 2006, Journal of medical microbiology.

[49]  H. Michie The value of animal models in the development of new drugs for the treatment of the sepsis syndrome. , 1998, The Journal of antimicrobial chemotherapy.

[50]  V. Jennings Review of Selected Adjuvants Used in Antibody Production. , 1995, ILAR journal.

[51]  S. Lofthouse,et al.  Comparison of conventional adjuvants and 'adjuvant-free' monoclonal antibody targeting for stimulating antibody responses against a conjugate of luteinizing hormone releasing hormone and avidin. , 1993, Vaccine.